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Abstract
In medication adherence-promotion trials, participants in the intervention arm are often cognizant 
of the researcher’s aim to improve adherence; this may lead to their inflating reports of their own 
adherence compared to control arm participants. Using data from 1,247 HIV-positive participants 
across eight U.S. Studies in the Multisite Adherence Collaboration on HIV (MACH14) 
collaboration, we evaluated the validity of self-reported adherence by examining whether its 
association with two more objective outcomes [1], electronically monitored adherence and [2] 
viral load, varied by study arm. After adjusting for potential confounders, there was no evidence 
of greater overestimation of self-reported adherence among intervention arm participants, 
supporting its potential as a trial outcome indicator.
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Introduction
Patient self-report as a method for assessing medication adherence has come under scrutiny. 
This is in part due to pharmacological and technological advances capable of measuring 
medication ingestion in a less subjective fashion. Indeed, in the case of antiretroviral therapy 
(ART), overestimation of self-reported adherence in comparison to electronic drug 
monitoring (EDM) has long been reported [1]. More recently, in pre-exposure prophylaxis 
trials for HIV prevention, low serum levels of detectable drug have been discordant with 
high self-reported adherence [2, 3], suggesting that self-reports are biased upward. This 
effect is usually attributed to participants’ wanting to provide “socially desirable” responses; 
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however, three correlational studies examining the relation between social desirability 
(explicitly measured) and self-report adherence found no such association [1, 4, 5].
In adherence-promotion trials, participants in the intervention arm typically receive 
information or resources to promote greater adherence with the clear message that better 
adherence is desired by the researchers. This may create another threat to the validity of self-
report occurs: demand characteristics [6]. Participants subject to demand characteristics 
know they are being evaluated with a specific goal in mind and then modify their behavior 
(or their reporting of the behavior) accordingly. To counteract demand characteristics, 
investigators often attempt to disguise the true purpose of the research. They may resort to 
deception in an attempt to “blind” participants to the study’s intent. However, in most 
behavioral research on adherence-promotion interventions, the intent of the study is difficult 
to mask. It is plausible that demand characteristics, compounded by the desire to be a 
“good” participant by providing socially desirable responses [7], may lead those in the 
intervention arm to overestimate their adherence to a greater degree than in the control arm 
(where adherence-promotion messages are generally less salient and systematic). If true, 
self-report of adherence might not be sufficiently rigorous for evaluating the efficacy of 
adherence interventions. We could locate no research that has systematically evaluated 
whether study arm assignment differentially affects the validity of self-reported adherence in 
studies to promote adherence to medications for HIV or other conditions, but it is a plausible 
hypothesis.
In the present study, we combined data from eight separate adherence-promotion 
interventions. We examined the association between self-reported adherence after the 
intervention phase and two other outcomes shown to be associated with self-reported 
adherence [1] but assumed to be less subjective or prone to demand characteristics: (a) EDM 
and (b) plasma HIV-1 viral load (VL). The null hypothesis was that there would be no 
difference in the overestimation of adherence between participants in either arm. We tested 
this by (a) comparing in each study arm the discrepancy between self-reported and EDM 
adherence and (b) assessing the moderation by arm of the association between self-reported 
adherence and both EDM and VL.
Methods
Data Source
Data came from the Multi-site Adherence Collaboration on HIV (MACH14), a National 
Institute of Mental Health-funded project combining data from 16 studies collecting EDM 
ART adherence data at 14 sites across the United States (U.S.) [8]. Demographic, 
psychosocial, and biological data from the individual studies were combined to create new 
variables in a pooled data set. The present study focused on eight behavioral studies 
conducted at seven research sites, representing 1,247 individuals, each including post-
intervention measures of (a) 3-day self-reported adherence (b) EDM ART adherence, and 
VL. Seven studies were excluded because they did not include an intervention with one or 
more control or comparison arms, and one study was excluded because it did not include a 
3-day self-report measure of adherence.
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Participant Characteristics
The final analytic sample of 1,247 participants ranged in age from 19 to 66 years and was 
mostly (67 %) male. Participants were 48 % African American, 33 % White, 13 % Latino, 
and 6 % Asian American. With respect to education, 66 % of participants possessed a high 
school or general education degree, and 13 % had at least some postsecondary education. 
Sixty-one percent were heterosexual and 39 % were gay or bisexual. The majority of 
participants (86 %) were starting an ART regimen for the first time at baseline. With respect 
to ART regimens, 90 % of participants were prescribed a regimen that included a nucleoside 
or nucleotide reverse transcriptase inhibitor, 56 % included a protease inhibitor, 41 % 
included a non-nucleoside reverse transcriptase inhibitor, and <1 % included a fusion or 
integrase inhibitor.
Measures
Demographic characteristics
Demographic variables included as covariates were: age; sex; race/ethnicity; education; 
sexual orientation (gay or bisexual versus heterosexual); education (less than high school 
diploma, completed high school, some college or higher); and whether ART-experienced or 
ART-naïve.
Self-reported ART Adherence
The analyses used participant self-report of medication adherence from each available 
assessment following the intervention phase of the study (when, presumably, participants 
would be most primed to overestimate their adherence). To assess adherence, the different 
studies generally used modifications of the Adult AIDS Clinical Trial Group Instrument [9], 
which includes, for each antiretroviral medication the participant was prescribed, separate 
questions assessing the number of doses missed yesterday, the day before yesterday, and 
three days ago. From these data, we determined the 3-day dose adherence averaged across 
all ART medications, calculated as the fraction of doses taken during the 3-day period over 
the total number of doses prescribed.
EDM ART
Adherence Every study included an EDM device, a pill bottle and cap that electronically 
records the date and time of each opening as a presumptive dose. Post-intervention EDM 
adherence was calculated for the 3-day time frames of each available self-report assessment 
as the number of openings (i.e., presumptive doses taken) divided by the total number of 
doses prescribed. For individuals with multiple post-intervention assessments, a 
corresponding 3-day EDM score was calculated for each available self-report assessment. 
For individuals with more than one medication monitored, percent EDM adherence was 
averaged across all of the monitored antiretroviral (ARV) medications.
HIV-1 RNA VL
Laboratory-assessed plasma HIV-1 RNA VL was evaluated as a clinical outcome using the 
VL measurement closest in time to each SR adherence assessment (Mean = 45 days, 95 % 
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CI = [41, 49]). Because of differences in test sensitivity across study sites, we defined a 
uniform minimum quantifiable VL of 400 copies/mL to allow for a consistent clinically 
relevant cutoff across individuals and studies. As VL data were positively skewed, we 
applied a log10 transformation and utilized the log-transformed values in all statistical 
analyses.
Statistical Analysis
Because the data originated from multiple studies, we first conducted preliminary analyses 
to assess for any site-specific associations between the outcome variables and the 
demographic and self-report adherence variables. For each of these predictor variables, the 
EDM adherence and VL outcomes were regressed on site, the predictor, and the predictor by 
site interaction in a single multivariate model. An omnibus Wald χ2 test of the predictor by 
site interactions evaluated whether the relation between the predictor and each outcome 
varied by study site.
The race/ethnicity by site interaction was significant for VL, indicating a statistically 
significant difference in the association between race and VL across study sites. 
Consequently, we controlled for the main effect of site and its interaction with race in the 
final model of the VL outcome. There were no other statistically significant interactions by 
site for any for any of the other predictors. Site effects were modeled using fixed effects 
because of the small number of clusters. As site was not of substantive interest in the final 
results, we report the average predictor effect weighted by the relative sample size of the 
sites included in the analysis.
In the main analyses, a multivariate generalized estimating equation (GEE) model was used 
to evaluate if the association of self-reported adherence with (a) EDM adherence and (b) 
log10 HIV VL varied between individuals randomized to active treatment versus control. 
We controlled for potential demographic confounders. The statistical test of moderation was 
the self-reported adherence by treatment arm interaction, which was modeled separately for 
EDM adherence and VL. Omnibus Wald χ2 tests evaluated whether treatment assignment 
moderated the association of self-reported adherence across both outcomes. GEE is a 
multilevel regression technique that adjusts standard errors to account for correlated 
outcomes and can accommodate both repeated measures and multiple dependent variables. 
This permitted the association of self-reported adherence with both EDM adherence and VL 
to be evaluated in a single multivariate longitudinal regression model. The model was 
estimated with an exchangeable correlation structure, which assumes equal correlations 
among outcome measurements. A robust standard error correction was used to 
accommodate the non-normal distribution of the EDM and VL outcomes and to 
accommodate departures from compound symmetry.
To retain participants with missing covariate or outcome data in the moderation analyses 
with GEE, multiple imputation was performed using the multivariate normal method. This 
insured that the analytic sample was consistent across both of the outcomes in the model. 
Since the adherence and VL outcomes were assessed at multiple time points, intra-individual 
correlations in these measures were adjusted for clustering among participants [10]. All 
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analyses were replicated across ten imputed datasets, with the final results calculated as a 
pooled average of the individual analyses.
Results
Descriptive Analyses
Analyses of the unimputed post-baseline data indicated overall adherence as estimated by 
self-report was 91.28 % (95 % CI = [90.28, 92.28]), approximately 26 % points higher than 
EDM adherence-66.68 % (95 % CI = [64.23, 69.14]). More than half of the participants had 
achieved an undetectable viral load post-baseline-55.08 % (95 % CI = [51.90, 58.27]). 
Average post-baseline indicators by study arm are presented in Table 1. Note that the mean 
difference between self-reported and EDM adherence was nearly identical for control arm 
(25.25 % [21.59, 28.91]) and intervention arm (26.11 % [22.83, 29.39] participants, 
providing little evidence of overestimation of adherence by arm in the raw, unimputed data.
Multivariate Longitudinal Regression Analysis
Table 2 shows the results of the GEE model evaluating for moderation due to treatment 
assignment in the association of self-reported adherence with the EDM adherence and VL 
outcomes. SR adherence had a statistically significant association with both EDM adherence 
and VL, while study arm assignment was not significantly associated with either. The 
omnibus test of the moderation effect was not statistically significant (F [2, 511.3] = 0.53, p 
= 0.59), indicating no evidence that the degree of association between self-reported 
adherence and either of the two outcomes varied by intervention arm assignment. The 
univariate self-reported adherence by intervention interaction was also not statistically 
significant for EDM adherence (Beta = 0.04, SE = 0.05, p = 0.42) or VL (Beta = −0.12, SE 
= 0.16, p = 0.46), indicating that the non-significant omnibus finding did not obscure a 
significant moderation effect in either of the outcomes. Thus, there was no evidence that 
participants, whether assigned to active treatment or control, estimated their adherence 
differently with respect to either EDM adherence or VL.
Discussion
We investigated whether participants in trials evaluating ART adherence promotion 
strategies who were in the intervention arm were more likely than those in the control arm to 
succumb to demand characteristics and inflate self-reports of adherence. Findings from this 
analysis of 1,247 participants across eight U.S. Studies in the MACH14 collaboration 
provided no evidence that they were. Specifically, multivariate regression models indicated 
no interaction effect for self-reported adherence and study arm assignment for either EDM 
adherence or VL outcomes (despite a positive association between self-report and both 
EDM adherence and VL). Moreover, mean overestimates of self-reported adherence 
compared to EDM were nearly identical in each arm.
Three other studies that explicitly measured social desirability found no relation between it 
and self-reported adherence [1, 4, 5]. This suggests that even if social desirability differs 
between participants in intervention and control arms, this difference may not affect self-
reported adherence estimates. However, Nieuwkerk et al. [11] found that the association 
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between self-reported medication adherence and VL was statistically significant for Dutch 
HIV patients indicating low social desirability but not for patients indicating high social 
desirability. This would mean that if social desirability does differ between arms, it could 
have an effect on the accuracy of self-reported adherence estimates. Future work will need 
to explicitly measure social desirability in each study arm to confirm this. It could also be 
important for those evaluating adherence interventions to know if social desirability plays a 
greater role for specific populations or in certain contexts.
Limitations of our study included our exclusive use of a 3-day adherence measure (results 
may vary with other measures of self-reported adherence, particularly those with a longer 
time frame); high levels of self-reported adherence with little variance (that may produce 
ceiling effects); linear models (actual associations may be nonlinear); the variation in time 
between self-reported adherence assessment and VL results; and the potential for pre-
existing resistance precluding virologic response that were not taken into account in this 
analysis. However, both self-report and EDM-measured adherence were associated with 
viral load, suggesting our models were able to detect important sources of variability when 
they were present. Additionally, the associations among key variables within each study arm 
were nearly identical, further suggesting low power was not a factor in the null findings. 
Finally, though we did control for potentially confounding socio-demographic factors, there 
may be additional variables not readily accessible in this pooled data set (e.g., dosing 
schedule) that obscure an actual moderation.
Limitations notwithstanding, our findings suggest self-report may constitute a valid outcome 
for the purposes of intervention efficacy evaluations, especially in real-world settings where 
more expensive assessments such as EDM are not feasible. This knowledge is relevant for 
work in diseases other than HIV such as diabetes, in which intervention efficacy can be 
evaluated with both self-report and biomedical indicators.
Note our conclusion is tempered by reports that self-reported adherence has been 
consistently shown to inflate adherence relative to more “objective” measures [1]. Indeed, in 
the present study, self-report overestimated adherence compared to EDM by an average of 
26 percentage points. Thus, while we found no evidence that self-reported adherence 
estimates vary in accuracy according to arm, they are still likely to overestimate actual 
medication ingestion. If these overestimates of adherence by participants in both arms lead 
to ceiling effects, this could result in Type II error in the evaluation of intervention efficacy.
Ultimately, inexpensive, passive, non-intrusive adherence assessment technologies may 
become widely available for use in clinical trials of adherence-promotion interventions; 
meanwhile, self-report of adherence should not be categorically dismissed as a potential 
outcome indicator.
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Table 1
Post-Baseline Outcome Indicators Across 8 Adherence-Promotion Trials (Mean and 95 % Confident Intervals) 
by Study Arm (N = 1,247)
Indicator Control Arm Intervention Arm
Self-reported 3-day adherence 91.01 [89.45, 92.52] 91.49 [90.16, 92.81]
Electronically monitored adherence 67.16 [63.45, 70.87] 66.30 [63.03, 69.56]
VL (% undetectable) 51.92 [41.65, 50.56] 57.50 [53.26, 61.74]
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